Therapeutic Drug Monitoring of Blood Sirolimus and Tacrolimus Concentrations for Polypharmacy Management in a Lymphangioleiomyomatosis Patient Taking Two Cytochrome P450 3A Inhibitors
The Tohoku Journal of Experimental Medicine · 2023
DOI: 10.1620/tjem.2023.j016 ↗Kurz gefasst
Fallbericht in der Zeitschrift The Tohoku Journal of Experimental Medicine, 2023. Verfasst von Masaki Kumondai und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, Tohoku University Hospital. Hauptthemen laut MEDLINE: Tacrolimus, Lymphangioleiomyomatosis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Themen: Medikationssicherheit
Abstract (Originalsprache)
Patients with lymphangioleiomyomatosis (LAM) and lung transplantations are treated with multiple drugs, such as tacrolimus, mycophenolate mofetil, prednisolone, and itraconazole, for long-term suppression of rejection response and prevention of infection. Additional drugs are required when lung transplant recipients develop graft complications. Therefore, managing polypharmacy is critical because of drug-drug interactions caused by various factors, including drug-metabolizing enzymes such as cytochrome P450 3A (CYP3A). The patient was a 48-year-old woman (height 144.9 cm and weight 38.4 kg) who underwent lung transplantation for LAM. Mycophenolate mofetil, tacrolimus (target blood concentration, 4.0-8.0 ng/mL), and prednisolone were administered for immunosuppression, and itraconazole and clarithromycin were administered to manage graft infection. The patient developed unilateral lymphedema, predominantly in the left leg; therefore, sirolimus was initiated with a target blood concentration of 3.0-5.0 ng/mL. In addition to 1.0 mg/day of sirolimus, tacrolimus (0.3 mg/day), itraconazole (100 mg/day), and clarithromycin (800 mg/day) were added. Blood sirolimus concentrations ranged from 18.8 to 36.9 ng/mL on days 6 to 9; thus, treatment with sirolimus was stopped because of over-target blood concentrations. Blood concentrations of sirolimus and tacrolimus were successfully managed without adverse events using therapeutic drug monitoring (TDM) and azole anti-fungal substitution of azithromycin instead of clarithromycin although sirolimus concentration was relatively lower compared to the target range. Thereby, frequent TDM, management of polypharmacy that influences CYP3A activity, and possibly CYP3A genotyping should be appropriately conducted for personalized medicine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, Tohoku University Hospital.
- Faculty of Pharmaceutical Sciences, Tohoku University.
- Department of Thoracic Surgery, Tohoku University Hospital.
Zitieren
APA
Kumondai, M., Kikuchi, M., Mizuguchi, A., Hayashi, N., Ui, M., Hirama, T., Okada, Y., Sato, Y., Sato, T., Maekawa, M., & Mano, N. (2023). Therapeutic Drug Monitoring of Blood Sirolimus and Tacrolimus Concentrations for Polypharmacy Management in a Lymphangioleiomyomatosis Patient Taking Two Cytochrome P450 3A Inhibitors. The Tohoku Journal of Experimental Medicine. https://doi.org/10.1620/tjem.2023.j016
Vancouver
Kumondai M, Kikuchi M, Mizuguchi A, Hayashi N, Ui M, Hirama T, et al. Therapeutic Drug Monitoring of Blood Sirolimus and Tacrolimus Concentrations for Polypharmacy Management in a Lymphangioleiomyomatosis Patient Taking Two Cytochrome P450 3A Inhibitors. The Tohoku Journal of Experimental Medicine. 2023. doi:10.1620/tjem.2023.j016
BibTeX
@article{Kumondai2023,
author = {Kumondai, Masaki and Kikuchi, Masafumi and Mizuguchi, Atsushi and Hayashi, Nagomi and Ui, Masahiro and Hirama, Takashi and Okada, Yoshinori and Sato, Yu and Sato, Toshihiro and Maekawa, Masamitsu and Mano, Nariyasu},
title = {Therapeutic Drug Monitoring of Blood Sirolimus and Tacrolimus Concentrations for Polypharmacy Management in a Lymphangioleiomyomatosis Patient Taking Two Cytochrome P450 3A Inhibitors},
journal = {The Tohoku Journal of Experimental Medicine},
year = {2023},
doi = {10.1620/tjem.2023.j016}
}
EUVIMED